NEW YORK, November 19, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Illumina Inc. (NASDAQ: ILMN), Epizyme, Inc. (NASDAQ: EPZM), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and Endocyte, Inc. (NASDAQ: ECYT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Illumina Inc. Research Report
On November 11, 2013, Illumina Inc. (Illumina) announced the appointment of Francis deSouza to the role of President. According to the Company, deSouza will report to CEO Jay Flatley and will lead Illumina's business units and the core functions responsible for envisioning, developing and producing the Company's products. deSouza will also become part of Illumina's executive management team, which is responsible for directing all aspects of company strategy, planning and operations. According to Illumina, deSouza has nearly two decades of technology experience and has successfully brought products to market in startups as well as large organizations. The Full Research Report on Illumina Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Epizyme, Inc. Research Report
On November 14, 2013, Epizyme, Inc. (Epizyme) announced initial findings from an ongoing Phase 1 study of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT) being developed for the treatment of acute leukemia with alterations in the MLL gene. CEO Robert J. Gould, Ph.D., said, "EPZ-5676 is a first-in-class inhibitor of the DOT1L HMT, and we are very pleased with the findings to date in the dose escalation stage of the ongoing two-stage Phase 1 study. The safety, pharmacokinetic, pharmacodynamic, and treatment effects observed in this study are consistent with our pre-clinical data. Based on these results, we plan to initiate the MLL-r only Phase 1 expansion stage in December 2013 and pediatric MLL-r and MLL-PTD studies in early 2014." Based on the said results, Epizyme plans to start the Phase 1 MLL-r only expansion stage with an 80 mg/m2/day administration schedule without a drug holiday and with possible continued dose escalation. The Company reported that this expansion stage is intended to provide an initial assessment of efficacy for EPZ-5676 in MLL-r patients. The Full Research Report on Epizyme, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Questcor Pharmaceuticals, Inc. Research Report
On November 12, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced the addition of G. Kelly Martin, President and CEO of Elan Corporation, plc, to Questcor's Board of Directors Questcor informed that the addition has brought the number of directors to eight, seven of whom are independent. According to Questcor, Martin has served as Elan's President, CEO, and a member of its Board of Directors since February 2003. The Company further informed that during Martin's tenure, he led a strategic plan to restructure Elan's business; built a diverse portfolio of scientific, clinical and therapeutic assets; and improved Elan's balance sheet by eliminating $4.5 billion in debt and obligations and strengthening its cash position. According to the Company, Elan's market capitalization grew from approximately $500 million when Martin joined Elan in February 2003 to over $8.5 billion when Elan announced its proposed sale to Perrigo Inc. in July 2013. The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Infinity Pharmaceuticals Inc. Research Report
On November 11, 2013, Infinity Pharmaceuticals Inc. (Infinity) announced that its presentation at the Credit Suisse 2013 Healthcare Conference, originally scheduled for November 13, 2013, has been rescheduled to November 12, 2013, at 10:00 a.m. ET (8:00 a.m. MT). The Full Research Report on Infinity Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Endocyte, Inc. Research Report
On November 7, 2013, Endocyte, Inc. (Endocyte) announced that Colin Goddard, Ph.D., has joined Endocyte's board of directors. According to the Company, Dr. Goddard is CEO and Chairman of Coferon, Inc. (Coferon), a privately held biotechnology company, and director of the biotech companies Agendia and PanOptica as well as an advisor to venture capital firms. Prior to joining Coferon, Dr. Goddard was CEO of OSI Pharmaceuticals (OSI), leading the company through its transition from a technology platform to profitable biopharmaceutical company, until its acquisition by Astellas Pharma for $4 billion. Dr. Goddard joined OSI as a scientist in 1989, and served as President and Chief Operating Officer before assuming the CEO role in 1998. The Full Research Report on Endocyte, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner